Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian Cancer

22 Aug 2013

Abstract excerpt

PURPOSE: We aimed to identify DNA methylation biomarkers of progression-free survival (PFS) to platinum-based chemotherapy in high-grade serous ovarian cancer (HGSOC) within biologically relevant ovarian cancer-associated pathways. EXPERIMENTAL DESIGN: Association with PFS of CpG island (CGI) promoter DNA methylation at genes in the pathways Akt/mTOR, p53, redox, and homologous recombination DNA repair was sought...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 23965899
DOI: 10.1158/1078-0432.ccr-13-1217

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Promoter CpG Island Methylation of Genes in Key Cancer Pathways Associates with Clinical Outcome in High-Grade Serous Ovarian CancerPMID 23965899Read ↗

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinomaSemantic proximity Read ↗

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read ↗

Exploration of differential methylation-driven genes to identify key epigenetic genes for prognosis of ovarian serous cystadenocarcinomaSemantic proximity Read ↗

Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patientsSemantic proximity Read ↗

Prognostic relevance of HRDness gene expression signature in ovarian high-grade serous carcinoma; JGOG3025-TR2 study.Semantic proximity Read ↗

Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium.Semantic proximity Read ↗

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer.Semantic proximity Read ↗

Molecular Characterization of Non-responders to Chemotherapy in Serous Ovarian Cancer.Semantic proximity Read ↗

Progression-Free Survival in Ovarian Cancer Is Reflected in Epigenetic DNA Methylation ProfilesSemantic proximity Read ↗

DNA methylation and transcriptomic features are preserved throughout disease recurrence and chemoresistance in high grade serous ovarian cancersSemantic proximity Read ↗

Plasma cfDNA methylation markers for the detection and prognosis of ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.